Latest Ratios: P/E Ratio 38.5x · EV/EBITDA 19.9x · ROE 7.1%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $137.4B | $162.8B | $169.2B | $171.9B | $173.4B | $214.9B | $141.5B | $98.7B | $64.9B | $58.1B | $48.3B |
| Enterprise Value | $151.2B | $176.6B | $184.3B | $185.6B | $188.0B | $235.6B | $157.7B | $101.3B | $73.9B | $68.0B | $59.6B |
| P/E Ratio → | 38.53 | 45.42 | 43.39 | 36.26 | 24.41 | 33.87 | 40.27 | 39.66 | 24.51 | 23.31 | 18.90 |
| P/S Ratio | 5.59 | 6.62 | 7.09 | 7.20 | 6.51 | 7.30 | 6.35 | 5.51 | 3.81 | 3.17 | 2.86 |
| P/B Ratio | 2.63 | 3.10 | 3.42 | 3.21 | 3.46 | 4.76 | 3.56 | 3.26 | 2.30 | 2.20 | 2.09 |
| P/FCF | 26.13 | 30.94 | 31.95 | 29.74 | 23.54 | 30.42 | 26.13 | 29.76 | 18.88 | 19.98 | 16.47 |
| P/OCF | 21.42 | 25.37 | 25.30 | 24.00 | 20.36 | 25.71 | 22.80 | 24.98 | 16.14 | 16.71 | 13.71 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.19 | 7.72 | 7.77 | 7.06 | 8.00 | 7.08 | 5.66 | 4.33 | 3.71 | 3.53 |
| EV / EBITDA | 19.94 | 23.28 | 24.45 | 24.93 | 19.45 | 23.05 | 25.90 | 22.26 | 17.39 | 15.50 | 14.48 |
| EV / EBIT | 29.44 | 39.25 | 37.43 | 34.80 | 25.57 | 30.05 | 33.07 | 29.68 | 23.84 | 21.92 | 21.32 |
| EV / FCF | — | 33.57 | 34.80 | 32.10 | 25.52 | 33.35 | 29.11 | 30.55 | 21.49 | 23.39 | 20.32 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.9% | 60.9% | 59.5% | 58.7% | 60.8% | 61.0% | 56.0% | 55.7% | 55.8% | 55.8% | 55.6% |
| Operating Margin | 20.9% | 20.9% | 21.7% | 22.1% | 28.3% | 27.3% | 19.4% | 18.8% | 18.0% | 17.2% | 17.7% |
| Net Profit Margin | 14.7% | 14.7% | 16.3% | 19.9% | 27.1% | 21.8% | 16.4% | 14.3% | 15.5% | 13.6% | 15.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.1% | 7.1% | 7.6% | 9.2% | 15.1% | 15.1% | 10.4% | 8.7% | 9.7% | 10.1% | 10.9% |
| ROA | 4.5% | 4.5% | 4.8% | 5.6% | 8.6% | 8.1% | 5.3% | 4.7% | 5.6% | 5.4% | 5.5% |
| ROIC | 5.9% | 5.9% | 5.9% | 6.0% | 8.7% | 9.9% | 7.3% | 7.2% | 6.3% | 6.7% | 6.4% |
| ROCE | 7.0% | 7.0% | 7.1% | 6.9% | 10.0% | 11.2% | 6.8% | 6.7% | 7.2% | 7.8% | 7.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.35 | 0.35 | 0.35 | 0.37 | 0.41 | 0.52 | 0.56 | 0.74 | 0.35 | 0.40 | 0.53 |
| Debt / EBITDA | 2.43 | 2.43 | 2.28 | 2.62 | 2.13 | 2.28 | 3.64 | 4.95 | 2.29 | 2.40 | 2.98 |
| Net Debt / Equity | — | 0.26 | 0.30 | 0.26 | 0.29 | 0.46 | 0.41 | 0.09 | 0.32 | 0.38 | 0.49 |
| Net Debt / EBITDA | 1.82 | 1.82 | 2.00 | 1.84 | 1.51 | 2.02 | 2.65 | 0.57 | 2.11 | 2.25 | 2.75 |
| Debt / FCF | — | 2.62 | 2.85 | 2.36 | 1.98 | 2.93 | 2.98 | 0.79 | 2.60 | 3.40 | 3.86 |
| Interest Coverage | 16.97 | 16.97 | 17.71 | 18.45 | 35.52 | 32.53 | 17.47 | 31.44 | 22.64 | 19.06 | 15.16 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.87 | 1.87 | 1.40 | 1.68 | 1.89 | 1.43 | 1.86 | 5.19 | 1.47 | 1.43 | 0.97 |
| Quick Ratio | 1.51 | 1.51 | 1.05 | 1.37 | 1.56 | 1.09 | 1.55 | 4.86 | 1.13 | 1.05 | 0.72 |
| Cash Ratio | 0.68 | 0.68 | 0.31 | 0.71 | 0.71 | 0.32 | 0.82 | 4.04 | 0.16 | 0.13 | 0.14 |
| Asset Turnover | — | 0.29 | 0.31 | 0.28 | 0.32 | 0.35 | 0.29 | 0.29 | 0.36 | 0.39 | 0.37 |
| Inventory Turnover | 3.86 | 3.86 | 4.15 | 3.80 | 3.78 | 4.16 | 4.28 | 4.87 | 4.62 | 4.40 | 4.39 |
| Days Sales Outstanding | — | 58.13 | 67.11 | 70.85 | 69.38 | 67.45 | 78.79 | 66.60 | 66.62 | 70.13 | 68.88 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.6% | 0.5% | 0.5% | 0.5% | 0.5% | 0.3% | 0.4% | 0.5% | 0.7% | 0.7% | 0.8% |
| Payout Ratio | 24.3% | 24.3% | 19.7% | 17.2% | 11.3% | 11.5% | 16.9% | 20.6% | 16.3% | 15.2% | 15.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.6% | 2.2% | 2.3% | 2.8% | 4.1% | 3.0% | 2.5% | 2.5% | 4.1% | 4.3% | 5.3% |
| FCF Yield | 3.8% | 3.2% | 3.1% | 3.4% | 4.2% | 3.3% | 3.8% | 3.4% | 5.3% | 5.0% | 6.1% |
| Buyback Yield | 2.2% | 1.9% | 3.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 2.9% | 2.4% | 4.0% | 0.5% | 0.5% | 0.3% | 0.4% | 0.5% | 0.7% | 0.7% | 0.8% |
| Shares Outstanding | — | $711M | $737M | $743M | $737M | $737M | $719M | $726M | $710M | $706M | $700M |
Bioprocessing demand normalization
According to current market data, Danaher trades at a forward P/E of 23.19, which suggests that investors are pricing in a significant premium for the company's recurring revenue model and its historical ability to deploy the Danaher Business System to drive margin expansion across its portfolio.
The current P/E of 38.82 on a trailing basis appears elevated, reflecting the market's anticipation of a return to historical growth rates following the recent portfolio spin-offs. Investors should monitor whether this valuation multiple remains sustainable if bioprocessing demand continues to face normalization headwinds, as the current price implies a high degree of confidence in future earnings accretion.
Based on reported financial figures, Danaher's ROIC has fluctuated between 1.1% and 2.0% over the last ten quarters, indicating that the company is currently navigating a period where significant capital deployment into acquisitions has yet to fully translate into optimized returns on invested capital.
The relatively low ROIC levels appear to be heavily influenced by the substantial goodwill and intangible assets added through recent large-scale acquisitions. This suggests that the company's ability to compound returns will depend heavily on its success in integrating these assets and achieving the expected operational synergies within its core life sciences and diagnostics segments.
As reported in recent quarterly filings, Danaher's cash conversion cycle has remained elevated, peaking at 108 days in 2025Q2, which reflects the complexities of managing inventory levels across a global diagnostic and bioprocessing supply chain during a period of post-pandemic demand rebalancing.
The fluctuation in days inventory outstanding, which reached 120 days in 2025Q2, suggests that the company is carrying significant inventory buffers to mitigate supply chain risks. While this provides operational security, it may indicate a temporary drag on efficiency that warrants further investigation as the company works to normalize its working capital requirements.
Based on the provided financial statements, Danaher maintains a stable debt-to-equity ratio of 0.35, which indicates a conservative capital structure that provides the company with significant flexibility to pursue accretive M&A opportunities despite the current high-interest-rate environment and sector-specific volatility.
The company's interest coverage ratio, which has remained consistently above 10x, suggests that debt service remains well-supported by operating cash flows. This healthy leverage profile appears to be a key pillar of the company's strategy, allowing it to maintain its investment-grade status while navigating the capital-intensive nature of its life sciences business.
The price-to-earnings ratio is frequently misapplied to Danaher, as it obscures the significant non-cash amortization charges resulting from the company's aggressive M&A strategy, which can artificially depress GAAP earnings and lead to an inaccurate assessment of the company's true underlying cash-generative earning power.
Investors should instead focus on free cash flow multiples or adjusted EBITDA, which better reflect the cash-generative nature of the company's recurring consumable revenue streams. Relying solely on P/E may lead to an overestimation of valuation risk, as it fails to account for the structural cash flow advantages inherent in the Danaher Business System.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DHR stock.
Danaher Corporation's current P/E ratio is 38.5x. The historical average is 21.4x. This places it at the 87th percentile of its historical range.
Danaher Corporation's current EV/EBITDA is 19.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 13.5x.
Danaher Corporation's return on equity (ROE) is 7.1%. The historical average is 13.8%.
Based on historical data, Danaher Corporation is trading at a P/E of 38.5x. This is at the 87th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Danaher Corporation's current dividend yield is 0.64% with a payout ratio of 24.3%.
Danaher Corporation has 60.9% gross margin and 20.9% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Danaher Corporation's Debt/EBITDA ratio is 2.4x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.